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                                    Two new approaches for the prevention of cervical cancer have 
emerged over the past decade: vaccination for the primary pre-
vention of human papillomavirus (HPV) infection in adolescent 
girls and the use of methods to detect infection with carcino-
genic HPV types, which allow secondary prevention via the 
identification and treatment of precancerous cervical lesions 
and early-stage cervical cancers. Population-based studies of 
HPV genotype prevalence are needed to predict how these two 
approaches might influence cervical cancer prevention and how 
prophylactic HPV vaccination of young women could affect the 
secondary prevention of cervical cancer. However, there have 
been relatively few studies of the distribution of HPV geno-
types in the United States. A recent survey from the National 
Health and Nutrition Examination Survey examined the preva-
lence of HPV genotypes in a population of women by using 
self-collected vaginal swab specimens (  1  ), which provided little 
insight to the HPV genotypes found in precancer and cancer. 
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     Background     Limited data are available describing human papillomavirus (HPV) genotype distributions in cervical can-
cer in the United States. Such studies are needed to predict how HPV vaccination and HPV-based screen-
ing will influence cervical cancer prevention.   
     Methods     We used the New Mexico Surveillance, Epidemiology, and End Results Registry to ascertain cases of in 
situ (n = 1213) and invasive (n = 808) cervical cancer diagnosed during 1985  –  1999 and 1980  –  1999, respec-
tively, in the state of New Mexico. HPV genotyping was performed using two polymerase chain reaction  –
  based methods on paraffin-embedded tissues from in situ and invasive cancers and on cervical 
Papanicolaou test specimen from control subjects (ie, women aged 18  –  40 years attending clinics for rou-
tine cervical screening [n = 4007]). Relative risks for cervical cancer were estimated, and factors associated 
with age at cancer diagnosis and the prevalence of HPV genotypes in cancers were examined.   
     Results     The most common HPV genotypes detected in invasive cancers were HPV type 16 (HPV16, 53.2%), HPV18 
(13.1%), and HPV45 (6.1%) and those in in situ       cancers were HPV16 (56.3%), HPV31 (12.6%), and HPV33 
(8.0%). Invasive cancer case subjects who were positive for HPV16 or 18 were diagnosed at younger ages 
than those who were positive for other carcinogenic HPV genotypes (mean age at diagnosis: 48.1 [95% 
confidence interval {CI} = 46.6 to 49.6 years], 45.9 [95% CI = 42.9 to 49.0 years], and 52.3 years [95% CI = 
50.0 to 54.6 years], respectively). The proportion of HPV16-positive in situ and invasive cancers, but not of 
HPV18-positive cancers, declined with more recent calendar year of diagnosis, whereas the proportion 
positive for carcinogenic HPV genotypes other than HPV18 increased.   
     Conclusions     HPV16 and 18 caused the majority of invasive cervical cancer in this population sample of US women, but 
the proportion attributable to HPV16 declined over the last 20 years. The age at diagnosis of HPV16- and 
HPV18-related cancers was 5 years earlier than that of cancers caused by carcinogenic HPV genotypes 
other than HPV16 and 18, suggesting that the age at initiation of cervical screening could be delayed in 
HPV-vaccinated populations.   
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examined HPV genotypes in parafﬁ  n-embedded tissues from 399 
invasive cervical cancer cases that were diagnosed in Washington 
State between 1986 and 1997, including 275 squamous cell carci-
nomas and 87 adenocarcinomas. Among the cancers in which 
HPV was detected, an unusually high percentage of squamous cell 
carcinomas (87%) and adenocarcinomas (86%) were positive for 
HPV type 16 (HPV16) and/or HPV18 compared with an interna-
tional series (  3  ,  4  ). Burger et al. (  5  ) evaluated HPV genotypes in 
fresh-frozen tissues from 291 cancer cases using HPV genotype  –
  speciﬁ   c polymerase chain reaction (PCR) primers speciﬁ  c  for 
HPV16, 18, and 6 in addition to a broad-spectrum HPV detection 
method, which led to a detection bias for those HPV genotypes. 
However, neither study included precancerous lesions, which are 
the target of cervical cancer screening programs. 
  To address this lack of data, we examined HPV genotypes in 
precancerous cervical lesions (carcinoma in situ [CIS] and adenocar-
cinoma in situ [AIS]) and invasive cervical cancers diagnosed in the 
state of New Mexico. We compared the HPV genotype distribution 
in these cases with that in a control sample of women aged 18  –  40 
years who were attending clinics in New Mexico for routine cervical 
screening. This control sample was chosen to represent the HPV 
genotype distribution in the source population for the cervical can-
cer cases. Our study design contrasts with the typical age-matched 
case  –  control study design in which, in the case of cervical cancer, 
older women would be selected as control subjects. Older women 
who test positive for HPV represent an unusual comparison group 
in that they are more likely to have persistent prevalent HPV infec-
tion (  6  ), which is a central risk factor for cervical precancer or can-
cer, and therefore are not representative of the population at risk. 
    Subjects and Methods 
    Selection of Case and Control Subjects 
  The aim of this study was       to provide a description of cervical can-
cer risk by HPV genotype, species, and risk groups. An additional 
aim, which is the subject of a separate report, included analyses of 
immunogenetic risk factors. This additional aim prohibited the 
inclusion of racial groups in which genetic studies were not feasible 
or for which sample sizes with adequate statistical power could not 
be achieved. The study was therefore restricted to Hispanic and 
non-Hispanic white women, who together represent approxi-
mately 90% of the female population of New Mexico. These stud-
ies were approved by the University of New Mexico Human 
Research Review Committee. 
  All cases of invasive cervical cancer diagnosed throughout the 
state of New Mexico from January 1, 1980, through September 30, 
1999, and all cases of CIS or AIS (ie, CIS/AIS) diagnosed at the 
University of New Mexico Hospital (UNMH) and Lovelace 
Medical Center (both in Albuquerque, NM) from January 1, 1985, 
through December 31, 1999, were identiﬁ  ed by the New Mexico 
Tumor Registry (NMTR). The NMTR is a member of the 
Surveillance, Epidemiology, and End Results (SEER) program of 
the US National Cancer Institute and has recorded the incidence 
of cancer in New Mexico since 1969. The NMTR assigns ethnicity 
based on information from multiple sources, including medical 
records, surname, Indian Health Service records, and death certiﬁ  -
cates. We validated the registry  ’  s coding of Hispanic and non-
Hispanic white ethnicity using data obtained from a case  –  control 
study of lung cancer in New Mexico, as previously described (  7  ). 
Approximately 40% of all CIS/AIS cases diagnosed in New Mexico 
during this time period (January 1, 1985, through December 31, 
1999) were diagnosed at UNMH or the Lovelace Medical Center. 
Mortality data for cases of cervical cancer included in this study 
were assessed through the end of November 2006. 
  Of 1429 cases of invasive cervical cancer diagnosed in Hispanic 
and non-Hispanic white women throughout New Mexico from 
1980 through 1999, a total of 808 women (57%) had parafﬁ  n-
embedded tissue blocks available for analysis. However, as a result 
of routine practice, many diagnostic tissues had been discarded 
after 10 years of archival storage, and therefore, only 42% 
(n = 283) of parafﬁ  n-embedded tissues for invasive cancers diag-
nosed from 1980 through 1989 were obtained. By contrast, 73% 
(n = 299) of parafﬁ  n-embedded tissues for invasive cancers diag-
nosed from 1990 through 1994 and 66% (n = 226) of those diag-
nosed from 1995 through 1999 were obtained. 
  Of 1530 cases of CIS/AIS diagnosed at UNMH and Lovelace 
Medical Center from 1980 through 1999, we were able to retrieve 
parafﬁ   n-embedded tissue specimens for the majority (79%; 
n = 1213): 49% (n = 173) of the CIS/AIS diagnosed from 1985 
through 1989, 74% (n = 391) of those diagnosed from 1990 through 
1994, and 99% (n = 649) of those diagnosed from 1995 through 1999. 
Parafﬁ  n-embedded tissues, corresponding pathology slides, and sur-
gical pathology reports were obtained for the primary diagnostic 
    CONTEXT AND CAVEATS 
    Prior knowledge 
  Vaccination of adolescent girls for the primary prevention of 
human papillomavirus (HPV) infection and methods to detect infec-
tion with carcinogenic HPV types have emerged as approaches for 
the prevention of cervical cancer. Population-based studies of HPV 
genotype prevalence are needed to predict how these approaches 
might influence cervical cancer prevention.   
    Study design 
  A case  –  control study of Hispanic and non-Hispanic white women in 
New Mexico to describe cervical cancer risk by HPV genotype, spe-
cies, and risk groups.   
    Contribution 
  HPV16 and 18 caused the majority of cervical cancer in this popula-
tion sample of US women. However, the proportion of HPV16-
positive cancers declined over the last 20 years, and age at 
diagnosis of HPV16- and HPV18-related cancers was 5 years earlier 
than that of cancers caused by other carcinogenic HPV genotypes.   
    Implications 
  The earlier age at diagnosis of HPV16- and HPV18-related cancers 
suggests that the age at initiation of cervical screening could be 
delayed in populations that are vaccinated against those HPV types.   
    Limitations 
  The findings may not be generalizable to other populations. 
Relationships between outcomes and time were inferred. 
Misattribution of some cases of cervical disease to HPV16 and 18 
was likely. 
    From the Editors       
    jnci.oxfordjournals.org    JNCI | Articles 477
specimen for each case using the initial date of diagnosis main-
tained in the NMTR database. Original pathology slides were 
reviewed by the study pathologist (N. E. Joste). When multiple 
parafﬁ  n-embedded tissues were present for a single case, the parafﬁ  n-
embedded tissue used for this analysis was selected in the following 
order of priority: the original cervical punch biopsy sample, fol-
lowed by the loop excision specimen, followed by the hysterec-
tomy specimen. The parafﬁ  n-embedded tissues selected for this 
analysis were subjected to a sandwich technique in which we 
obtained an initial 4-  µ  m tissue section for hematoxylin  –  eosin 
(H&E) staining, followed by three 4-  µ  m sections that were col-
lected in separate Eppendorf tubes for use in PCR assays, followed 
by up to four additional sections for additional testing that might 
require microdissection, and a ﬁ  nal 4-  µ  m section for H&E stain-
ing. The ﬁ  nal section was reviewed in a blinded fashion by the 
study pathologist for comparison with the community-based his-
tology diagnosis and to conﬁ  rm the presence of cervical cancer or 
lesion. The presence of either a cervical neoplastic lesion or cervi-
cal cancer was conﬁ  rmed in 87% of the samples: 81% of CIS/AIS 
and 96% of invasive cancers. When either a cervical lesion or can-
cer was conﬁ   rmed to be present, there was 94% agreement 
between the histology diagnosed by the study pathologist and the 
community-based histology (squamous, adenocarcinoma, ade-
nosquamous, or other): 96% for CIS/AIS and 91% for invasive 
cancers. All specimens, regardless of the conﬁ  rmed presence of 
cervical cancer or lesion, were used in this analysis. 
  Control samples consisted of fresh cervical swab specimens 
obtained from Hispanic and non-Hispanic white women 18  –  40 
years of age who attended the UNMH and Lovelace Medical 
Center for routine cervical screening. These women were enrolled 
from the clinic referral base for the CIS/AIS case subjects to repre-
sent the HPV exposure distribution in the source population of the 
cervical precancer and cancer case subjects. More than 4000 control 
subjects were enrolled in this study from July 1, 1996, through May 
31, 2000, after providing written informed consent. Women who 
self-reported their ethnicity as non-Hispanic white or Hispanic were 
invited to participate in this study. Enrollment exclusion criteria for 
control subjects included a history of high-grade squamous intraepi-
thelial lesions (HSILs) or cancer, hysterectomy, a history of cervical 
excision or ablative treatments, and a diagnosis of any cervical 
abnormality during the previous year. Fourteen control subjects 
who had a biopsy-conﬁ   rmed diagnosis of CIS/AIS during the 
enrollment period were reclassiﬁ  ed as case subjects. At the enroll-
ment visit, 90.9% of control subjects had a normal cytology diagno-
sis, 6.6% had a diagnosis of atypical squamous cells of undetermined 
signiﬁ  cance, 1.8% had a diagnosis of low-grade squamous intraepi-
thelial lesion, 0.5% had a diagnosis of HSIL, and 0.3% had a diag-
nosis of atypical glandular cells of undetermined signiﬁ  cance.   
    Laboratory Procedures 
  Control specimens were collected in specimen transport medium 
(1 mL; Digene Corp., Gaithersburg, MD) and frozen on the 
same day of collection at     85°C. The frozen samples were 
thawed, digestion solution (30   µ  L of 20 mg/mL proteinase K, 
10% laureth-12, 20 mM Tris, and 1 mM EDTA [pH 8.5]) was 
added to each specimen, and the mixtures were incubated at 60°C 
for 1 hour. A 300-  µ  L aliquot of the digested material was added 
to 1.0 mL of absolute ethanol containing 0.5 M ammonium ace-
tate, and the mixture was stored at     20°C overnight to allow the 
DNA to precipitate and then centrifuged for 30 minutes at 13 000  g  . 
The supernatant was discarded immediately, and the crude DNA 
pellet was dried overnight at room temperature. The pellet was 
suspended in 150   µ  L of 20 mM Tris and 1 mM EDTA (pH 8.5). 
A microcentrifuge tube cap lock (GeneMate; ISC BioExpress, 
Kaysville, UT) was placed on each microcentrifuge tube, and the 
tubes were incubated for 15 minutes at 95°C to inactivate the pro-
teinase K. The resulting crude DNA extracts were either used 
immediately for HPV genotyping or stored at     85°C. Crude 
DNA was obtained from paraffin-embedded tissue sections as 
previously described (  8  ). 
  HPV genotyping was performed using two different PCR-
based strategies. We initially used the PGMY09/11 line blot assay 
(LBA) on all samples, a PCR-based assay system that ampliﬁ  es a 
broad spectrum of HPV genotypes by targeting a 450-bp fragment 
within the L1 open reading frame (ORF) of the HPV genome and 
includes coampliﬁ  cation of an internal 248-bp fragment of the 
human     -globin gene to assess specimen adequacy (  9  ,  10  ). It is 
generally accepted that carcinogenic HPV genotypes are necessary 
causative agents of invasive cervical cancer (  11  ). Therefore, to 
overcome misclassiﬁ  cation of the HPV genotype resulting from 
potentially degraded DNA in aging archival parafﬁ  n-embedded 
tissues (ie, those archived for >5 years), we also used a second 
PCR-based strategy, the short fragment SPF10 LiPA25 system 
(version 1 assay; Labo Biomedical Products bv, Rijswijk, the 
Netherlands), which ampliﬁ  es a 65-bp fragment within the L1 
ORF (  12  ,  13  ) in supplementary analyses of the following subsets of 
parafﬁ   n-embedded case materials and control specimens: 1) all 
    -globin negative specimens, 2) all HPV (PGMY09/11 LBA)  –
  negative CIS/AIS and invasive cancer specimens and an equal 
number of randomly selected HPV (PGMY09/11 LBA)  –  positive 
specimens, and 3) a randomly selected sample of 50 HPV 
(PGMY09/11 LBA)  –  negative and 50 HPV (PGMY09/11 LBA)  –
  positive control specimens. We used the results of the SPF10 
LiPA25 system to assign the HPV genotype for HPV (PGMY09/11 
LBA)  –  negative CIS/AIS and invasive cancer specimens and for all 
    -globin  –  negative specimens. For all other specimens, the result 
of the PGMY09/11 LBA system was used to assign the HPV 
genotype. 
  The PGMY09/11 LBA and linear array (LA), a commercialized 
version of the LBA, and SPF10 LiPA25 assays have demonstrated 
  highly concordant results         previously in cervical scrape specimens 
(  14    –    16  ). No difference in the overall grouped detection of carcino-
genic HPV by the SPF10 LiPA25 and PGMY09/11 LA methods 
(35.3% vs 35.9%, respectively,   P   = .5) has been observed, with a 
91.8% overall agreement and a kappa of 0.82 (  16  ). PGMY09/11 
and SPF10 have differences in analytic sensitivity for a few indi-
vidual HPV genotypes and PGMY09/11 LA has been shown to 
have an increased sensitivity for detection of HPV coinfections 
(  14  ,  16  ). Thus, SPF10 primer systems have not been shown to be 
generally more sensitive for HPV detection than the PGMY09/11 
primer system. Rather because SPF10 primers target a smaller 
HPV L1 fragment, they have potential additional value if DNA is 
partially degraded into smaller fragments as a result of ﬁ  xation or 
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tissues does not appear to have differential speciﬁ  city for given 
DNA sequences. However, degradation can be directly related to 
the duration of ﬁ  xation (eg, time held in neutral buffered formalin) 
and the time since the specimen was originally embedded (  8  ). With 
regard to cervical scrape specimens, DNA degradation is minimal 
to nonexistent particularly when cervical specimens are collected 
in specimen transport medium and properly stored. 
  In this study, the SPF10 LiPA25 assay did not demonstrate a 
detection bias for any particular HPV genotype in parafﬁ  n-embedded 
tissues or cervical scrapes. Our goal in combining test results was to 
maximize the detection of HPV genotypes, rather than to evaluate 
the performance of any one test. Among the samples that tested posi-
tive for HPV by PGMY09/11 LBA and were retested by SPF10 
LiPA25, the crude percent agreement between the two assays was at 
least 95% for most HPV genotypes (  Supplementary Table 1  , avail-
able online). Importantly, there were no substantial differences 
between the two assays in the distribution of HPV genotypes in can-
cers (  Supplementary Table 2  , available online). Thus, combining the 
results did not inﬂ  uence the relative importance of HPV genotypes 
and also demonstrated that the results were not strongly inﬂ  uenced 
by the HPV genotyping system. 
  The PGMY09/11 PCR amplimers for all case and control 
specimens were subjected to reverse line blot hybridization (  9  ,  10  ) 
for detection of 27 HPV genotypes (HPV6, 11, 16, 18, 26, 31, 33, 
35, 39, 40, 42, 45, 51  –  59, 66, 68, 73 [PAP238a], 82 [W13b], 
83 [Pap291], and 84 [PAP155]). All control samples and all HPV 
DNA  –  negative case samples were also tested by reverse line blot 
hybridization for an additional 11 noncarcinogenic HPV geno-
types (HPV61, 62, 64, 67, 69  –  72, 81, 82 variant [IS39], and 
89 [CP6108]). 
  For the SPF10 LiPA25 PCR ampliﬁ  cations, the presence of 
HPV DNA amplimers was examined by hybridization to a mixture 
of HPV probes that recognize a broad range of at least 54 high-
risk, low-risk, and possible high-risk HPV genotypes in a DNA  –
  enzyme immunoassay microtiter plate format, as described 
previously (  12  ). Resultant amplimers were subjected to reverse line 
blot hybridization for detection of individual HPV genotypes. The 
SPF10 LiPA25 assay includes speciﬁ  c probes for the detection of 
25 HPV genotypes (HPV6, 11, 16, 18, 31, 33  –  35, 39, 40, 42  –  45, 
51  –  54, 56, 58, 59, 66, 68/73, 70, and 74).   
    Statistical Analysis 
  For the purpose of computing relative risks (RRs), we considered 
three different classifications of HPV: 1) HPV genotypes, 2) HPV 
species, and 3) a categorization based on an a priori risk of cervical 
cancer. We considered HPV species in addition to HPV genotypes 
because the species classification (  17  ) has been shown to predict 
the natural history and carcinogenicity of HPV genotypes within 
the species (  18  ), and it corroborates much of the recent risk assess-
ments defined by cross-sectional data from case  –  control studies 
and case series of cervical cancer (  3  ). In addition, phylogenetic clas-
sifications predict some viral patterns, such as the cross-protective 
effects of the L1 vaccine against HPV16 and 18 (  19  ,  20  ), HPV type 
representation in precancerous lesions (vs cancer) (  4  ), and the like-
lihood of causing cytological changes (  21  ), better than risk classifi-
cations. We used the following alpha species classification (  17  ): 
alpha-1 (HPV42), alpha-3 (HPV61, 62, 72, 81, 83, 84, 89), alpha-5 
(HPV26, 51, 69, 82, 82 variant IS39), alpha-6 (HPV53, 56, 66), 
alpha-7 (HPV18, 39, 45, 59, 68, 70), alpha-8 (HPV40, 43), alpha-9 
(HPV16, 31, 33, 35, 52, 58), alpha-10 (HPV6, 11, 44, 55, 74), 
alpha-11 (HPV34, 64, 73), alpha-13 (HPV54), and alpha-15 
(HPV71). 
  The a priori risk of cervical cancer (  2  ,  4  ) was classiﬁ  ed as follows 
(highest to lowest risk): 1) positive for HPV16 only; 2) if not posi-
tive for HPV16, then positive for HPV18; 3) if not positive for 
HPV16 or 18, then positive for other carcinogenic genotypes 
(HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, or 68); 4) if not posi-
tive for HPV16, 18, or any other carcinogenic HPV genotype, 
then positive for any remaining HPV genotype; and 5) HPV nega-
tive. It should be noted that this is a hierarchical classiﬁ  cation that 
results in mutually exclusive categories. Speciﬁ  cally, the number of 
case and control subjects classiﬁ  ed as HPV18 positive (category 2) 
will be less than the total number positive for HPV18 because 
category 2 excludes those that are also positive for HPV16. This 
mutually exclusive categorization is in contrast with the genotype 
and species classiﬁ  cations, in which subjects could be included in 
more than one category if they were infected with multiple HPV 
genotypes. 
  We estimated the relative risk as the case  –  control odds ratio 
and computed odds ratios separately for CIS/AIS and invasive 
cancers for the individual HPV genotypes or species using multi-
variable logistic regression. Indicator variables were included for 
each HPV genotype (or species), which allowed us to adjust for the 
presence of other HPV genotypes or species when estimating the 
case  –  control odds ratio. HPV genotypes 26, 55, 57, 61, 62, 64, 67, 
69  –  72, 81, 82, 82 variant IS39, 83, 84, and 89 were combined into 
a single “other” category because of low frequency (0 or 1 instance) 
in either CIS/AIS or invasive cancers. All odds ratios were adjusted 
for ethnicity (Hispanic vs non-Hispanic white). 
  We used subjects who were HPV16 positive as the referent 
category rather than HPV-negative subjects for several reasons. 
First, it is now generally accepted that there is virtually no risk of 
cervical precancer or cancer for women who are not infected with 
HPV (  11  ). Cases of CIS/AIS and invasive cervical cancer that test 
negative for HPV are, therefore, most likely the result of assay 
error. Speciﬁ  cally, in the case of archival tissues, HPV-negative 
cervical cancers may represent a failure to amplify the HPV DNA 
target due to degradation of the sample following ﬁ  xation in neutral-
buffered formalin. Second, we used HPV16-positive subjects as the 
referent category because HVP16 generally has the highest preva-
lence in women with normal cytology and in women with CIS/AIS 
or invasive cervical cancer (  3  ). In addition, there were sufﬁ  cient 
numbers of HPV16-positive subjects in all subgroups of case sub-
jects, which allowed us to use this group as a common referent 
category throughout our analyses. Another beneﬁ   t of using 
HPV16-positive subjects as the referent category is that we need 
only assume that the relative (vs absolute) frequency of HPV geno-
types in the control group is the same as that in the source popula-
tion of the case subjects. We interpret the case  –  control odds ratio 
as the risk of CIS/AIS or invasive cervical cancer for a speciﬁ  c 
HPV genotype or species relative to the risk for the HPV16-
positive group. These case  –  control odds ratios can also be inter-
preted as the ratio of two relative risks, each using the unexposed 
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  HPV18 and, to a lesser extent, HPV45 were previously 
reported to be underrepresented in precancerous lesions of the 
cervix compared with their prevalence in cancer (  4  ). This observa-
tion has direct implications regarding the HPV genotypes that 
might be preferentially missed by cytology screening. Therefore, 
we also computed the HPV prevalence ratio (PR) for invasive can-
cers vs CIS/AIS for each HPV genotype and species and for each 
category in the hierarchical risk classiﬁ  cation. These prevalence 
ratios are the crude (unadjusted) ratios of the frequency of each 
HPV type or species in invasive cancer to the corresponding fre-
quency in CIS/AIS. The 95% conﬁ  dence intervals (CIs) are based 
on the normal approximation to the binomial distribution. 
  We investigated the factors associated with age at diagnosis of 
CIS/AIS and invasive cancer using an analysis of variance model 
that included HPV hierarchical risk group, ethnicity, histology, 
stage at diagnosis, and calendar year of diagnosis as predictors. 
We also investigated the factors associated with the prevalence of 
HPV genotypes 16 and 18 in the combined sample of CIS/AIS 
and invasive cancer case subjects using a multinomial regression 
model that included age at diagnosis, ethnicity, calendar year of 
diagnosis, histology, and stage of diagnosis as predictors. Our a 
priori hypothesis was that HPV risk groups might be differen-
tially represented in various subgroups because of a number of 
factors, including secular trends due to cervical screening, aging 
in relation to the carcinogenicity of HPV risk groups, and HPV 
genotype  –  speciﬁ  c cell interactions. The multinomial regression 
model allowed us to control for the inﬂ  uence of these factors and 
to estimate the proportions of HPV risk groups within a sub-
group. Importantly, the model would enable us to predict the 
impact of HPV16/18 vaccination on each subgroup. All statistical 
analysis was done with SAS version 9.1 software (SAS Institute, 
Inc., Cary, NC), except for the multinomial regression, which 
was computed using SUDAAN version 9.0.1 software (Research 
Triangle Institute, Research Triangle Park, NC). All   P   values are 
two-sided, and   P   less than .05 was considered statistically 
signiﬁ  cant.     
    Results 
  Control subjects were predominantly Hispanic (57.0%), whereas 
the majority of case subjects were non-Hispanic white (58.9% and 
58.3%, for subjects with CIS/AIS and invasive cancer, respectively) 
(  Table 1  ). The majority of cancers (59.0%) were staged by the 
SEER program as local invasive (  22  ,   23  ), with decreasing numbers 
for more severe stages of cancer. Most CIS/AIS (95.9%) and inva-
sive cancers (81.7%) were diagnosed as having squamous cell his-
tology. Not surprisingly, the fraction of deaths attributable to 
cervical cancer increased with increasing severity of cancer stage at 
diagnosis, from 33.9% for local-stage invasive cancer to 71.4% for 
distant-stage invasive cancer.         
  The distributions of individual HPV genotypes in specimens 
from control subject and from CIS/AIS and invasive cancer case 
subjects are shown in   Table 2  . The prevalence of HPV in the con-
trol group specimens was 38.4%, and the most common HPV 
genotypes were HPV16 (7.4%), HPV53 (4.9%), and HPV54 
(3.5%). Most case specimens of CIS/AIS tested HPV positive 
(97.1%), and the most common genotypes were HPV16 (56.3%), 
HPV31 (12.6%), and HPV33 (8.0%). HPV18 was found in only 
5.9% of CIS/AIS. Most case specimens of invasive cancer tested 
HPV positive (91.0%), and the most common genotypes were 
HPV16 (53.2%), HPV18 (13.1%), and HPV45 (6.1%). HPV31 
and 33 were found in 12.6% and 8.0% of CIS/AIS, respectively, 
but in only 4% of invasive cancers. Among the HPV-positive 
specimens, multiple genotypes were detected in 687 (44.7%) of the 
control specimens, 215 (18.2%) of the CIS/AIS, and 62 (8.4%) of 
the invasive cancers. HPV frequencies using pooled results from 
the PGMY09/11 and SPF10 LiPA25 assays, which include an 
additional 11 noncarcinogenic HPV types, are shown in 
  Supplementary Table 3   (available online).         
  We used HPV16-positive subjects as the referent group when 
computing the case  –  control odds ratios and, therefore, interpret 
the odds ratio as a measure of the risk of CIS/AIS or invasive can-
cer for women infected with a speciﬁ  c HPV genotype relative to 
the risk for women exposed to HPV16. These odds ratios can also 
be interpreted as the ratio of two relative risks, each of which used 
the HPV-unexposed women as the referent group. For brevity, we 
refer to the case  –  control odds ratios as relative risks rather than as 
relative risk ratios and we have expressed the relative risk as a per-
centage so that HPV16 positivity had a relative risk of 100% and 
most of the other HPV genotypes had relative risks lower than 
100%. Among HPV33-positive women, the relative risk of CIS/
AIS was 101% (95% CI = 62% to 163%), which was essentially 
equal to that for HPV16-positive women and was consistent with 
a previous observation that HPV33 exposure posed a statistically 
signiﬁ  cant risk for cervical intraepithelial neoplasia grade 2 or 3 
(  24  ). Of the remaining HPV genotypes, only genotypes 31 and 35 
had relative risks for CIS/AIS that were statistically signiﬁ  cantly 
greater than 10% (HPV31: RR = 43%, 95% CI = 31% to 60%; 
HPV35: RR = 41%, 95% CI = 24% to 72%). The greatest risks of 
invasive cancer relative to HPV16 were observed for HPV18 
(RR = 68%, 95% CI = 47% to 100%), HPV33 (RR = 57%, 95% 
CI = 30% to 107%), HPV45 (RR = 32%, 95% CI = 20% to 53%), 
and HPV35 (RR = 22%, 95% CI = 11% to 47%). 
  The case subjects were diagnosed from 1980 through 1999, 
whereas the control subjects were recruited from 1996 through 
2000. Therefore, we also computed relative risks using only those 
precancers and invasive cancers that were diagnosed during 
1995  –  1999, a 5-year period that had the maximum overlap with 
the control subject enrollment period. (  Supplementary Table 4  , 
available online). The same pattern of relative risks was observed 
for this restricted sample of cases. 
  Relative risks of CIS/AIS and invasive cancer by HPV species 
are shown in   Table 3  . The HPV types in the alpha-9 group are 
HPV16, 31, 33, 35, 52, and 58. The alpha-7 group includes 
HPV18, 39, 45, 59, 68, and 70. The risk of CIS/AIS for HPV 
genotypes in the alpha-9 species (excluding HPV16) relative to 
HPV16 was 49% (95% CI = 39% to 62%). No other HPV species 
had a relative risk of CIS/AIS statistically signiﬁ  cantly greater than 
5%. The risk of invasive cancer for HPV genotypes in the alpha-9 
species (excluding HPV16) relative to HPV16 was 19% (95% CI = 
14% to 25%). HPV genotypes in the alpha-7 species had a similar 
relative risk of invasive cancer (RR = 19%, 95% CI = 15% to 26%). 
The risks of AIS and of adenocarcinoma for alpha-7 relative to 
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CI = 29% to 98%), respectively. Much of this risk was attributable 
to HPV18. When HPV18 was excluded, the risks of AIS and of 
adenocarcinoma for alpha-7 relative to HPV16 were 6% (95% 
CI = 1% to 66%) and 7% (95% CI = 2% to 19%), respectively 
(data not shown).         
  We next stratiﬁ  ed by histologic type (squamous cell carcinoma, 
adenocarcinoma, or adenosquamous carcinoma) and categorized 
the case and control subjects into one of ﬁ  ve mutually exclusive 
groups according to their a priori risk of cancer based on the 
results of the HPV genotyping (  Table 4  ). The relative risks of 
CIS/AIS were negligible for the HPV-negative and noncarcino-
genic HPV groups (RR = 0%, 95% CI = 0% to 0%, and RR = 2%, 
95% CI = 2% to 3%, respectively), whereas the carcinogenic HPV 
(excluding HPV16 and 18) and HPV18-positive groups had rela-
tive risks for CIS/AIS that were similar (RR = 30%, 95% CI = 25% 
to 36% and RR = 35%, 95% CI = 24% to 52%, respectively) but 
substantially smaller than that for the HPV16-positive referent 
group (100%). The relative risk of invasive cancer showed a similar 
  Table 1    .       Characteristics of study subjects  *     
    Characteristic
Control subjects 
(N       = 4007)
CIS/AIS case subjects 
(N = 1213)
Invasive cancer case 
subjects (N = 808) 
  n (%) n (%) n (%)   
    Year of diagnosis     
         1980  –  1984 0 (0.0) 0 (0.0) 100 (12.4) 
         1985  –  1989 0 (0.0) 173 (14.3) 183 (22.6) 
         1990  –  1994 0 (0.0) 391 (32.2) 299 (37.0) 
         1995  –  2000 4007 (100.0) 649 (53.5) 226 (28.0) 
  Age at interview or diagnosis, y     
         <20 353 (8.8) 66 (5.4) 1 (0.1) 
         20  –  24 1047 (26.1) 238 (19.6) 17 (2.1) 
         25  –  29 996 (24.9) 278 (22.9) 60 (7.4) 
         30  –  39 1477 (36.9) 405 (33.4) 199 (24.6) 
         40  –  49 119 (3.0) 136 (11.2) 170 (21.0) 
         50  –  59 0 (0.0) 55 (4.5) 123 (15.2) 
         60  –  69 0 (0.0) 23 (1.9) 123 (15.2) 
         70  –  79 0 (0.0) 9 (0.7) 77 (9.5) 
           ≥  80 0 (0.0) 3 (0.2) 38 (4.7) 
         Missing 15 (0.4) 0 (0.0) 0 (0.0) 
  Ethnicity     
         Non-Hispanic white 1725 (43.0) 714 (58.9) 471 (58.3) 
         Hispanic 2282 (57.0) 499 (41.1) 337 (41.7) 
  Stage at diagnosis    †        
         In situ   —  1213 (100.0) 0 (0.0) 
         Local   —  0 (0.0) 477 (59.0) 
         Regional   —  0 (0.0) 269 (33.3) 
         Distant   —  0 (0.0) 47 (5.8) 
         Unknown   —  0 (0.0) 15 (1.9) 
  Histology     
         Squamous   —  1163 (95.9) 660 (81.7) 
         Adenocarcinoma   —  23 (1.9) 101 (12.5) 
         Adenosquamous   —  2 (0.2) 21 (2.6) 
         Other   —  25 (2.1) 26 (3.2) 
  Vital status as of November 2006    ‡        
         Alive   —  1156 (95.3) 450 (55.7) 
         From cervical cancer   —  2 (0.2) 180 (22.3) 
         From other causes   —  55 (4.5) 178 (22.0) 
  Local-stage invasive cancer deaths     
         From cervical cancer   —   — 42  (33.9) 
         From other causes   —   — 82  (66.1) 
  Regional-stage invasive cancer deaths     
         From cervical cancer   —   — 105  (57.1) 
         From other causes   —   — 79  (42.9) 
        Distant-stage invasive cancer deaths     
         From cervical cancer   —   — 30  (71.4) 
         From other causes   —   — 12  (28.6) 
  Unknown-stage invasive cancer deaths     
         From cervical cancer   —   — 3  (37.5) 
         From other causes   —   — 5  (62.5)   
    *     CIS/AIS = carcinoma in situ or adenocarcinoma in situ;   —   = not applicable.   
      †       Surveillance, Epidemiology, and End Results historic A cancer staging was used (23).   
      ‡       Control subjects were not followed up for survival.     jnci.oxfordjournals.org    JNCI | Articles 481
pattern except that the risk for the HPV18-positive group was 
equal to that of the HPV16-positive group (RR = 100%, 95% CI = 
71% to 140%) and much larger than the relative risk of invasive 
cancer for the carcinogenic HPV group (excluding HPV16 and 18) 
(RR = 21%, 95% CI = 17% to 26%). When the analysis was 
restricted to adenocarcinoma and adenosquamous cell carcinoma, 
the risks of AIS and adenocarcinoma for the HPV18-positive 
group (RR = 430%, 95% CI = 168% to 1092%, and RR = 325%, 
95% CI = 187% to 561%, respectively) were much greater than 
the corresponding risks for the HPV16-positive referent group. 
There were no cases of AIS observed in the carcinogenic HPV 
(excluding HPV16 and 18)-positive group (RR = 0%, 95% CI = 
0% to 13%), and the relative risk of invasive adenocarcinoma for 
this group of HPV types was only 11% (95% CI = 5% to 23%).         
  To explore the relationship between invasive cancer and CIS/
AIS, we calculated HPV PRs (ie, the prevalence of HPV in invasive 
cancer relative to that in CIS/AIS) (data not shown). For all histo-
logical types combined, the prevalence of HPV18 was much 
higher in invasive cancers than in CIS/AIS (PR = 2.21, 95% CI = 
1.66 to 2.94) and exceeded the prevalence ratio for HPV16 (PR = 
0.95, 95% CI = 0.87 to 1.03). All other genotypes had PRs less 
than 0.75, with the exceptions of the alpha-7 genotypes HPV39 
(PR = 1.65, 95% CI = 0.91 to 3.01), HPV45 (PR = 1.99, 95% CI = 
1.31 to 3.02), and HPV59 (PR = 1.32, 95% CI = 0.67 to 2.64). As 
a group, the alpha-7 genotypes had a PR of 1.89 (95% CI = 1.55 
to 2.29) and excluding HPV18 did not substantially reduce the preva-
lence ratio (PR = 1.60, 95% CI = 1.19 to 2.14). The PR for alpha-7 
genotypes was 1.83 (95% CI = 1.47 to 2.26) for squamous cell histol-
ogy and for adenocarcinoma it was 0.65 (95% CI = 0.41 to 1.02). 
  By use of a multivariable analysis of variance approach, we also 
explored the determinants of age at diagnosis for CIS/AIS and 
invasive cancer (  Table 5  ). HPV risk group was statistically signiﬁ  -
cantly associated with the age at diagnosis of invasive cancer (  P   < 
.001) but not with the age at diagnosis of CIS/AIS (  P   = .15). 
Invasive cancer case subjects who were positive for HPV16 or 18 
were diagnosed at statistically signiﬁ  cantly younger mean ages than 
those who were positive for other carcinogenic HPV genotypes 
(mean age at diagnosis: 48.1 [95% CI = 46.6 to 49.6], 45.9 [95% 
CI = 42.9 to 49.0], and 52.3 years [95% CI = 50.0 to 54.6], respec-
tively;   P   = .0029 for HPV16 vs other carcinogenic HPV genotypes   
and   P   = .0013 for HPV18 vs other carcinogenic HPV genotypes). 
Locally invasive cancers were diagnosed at a statistically signiﬁ  -
cantly younger mean age than cancers that had presented with 
regional or distant metastases (mean age at diagnosis: 45.2 [95% 
CI = 43.8 to 46.6], 55.9 [95% CI = 54.0 to 57.8], and 55.1 [95% CI = 
50.6 to 59.6] years, respectively:   P   < .001 for both comparisons).         
  Finally, we examined how the relative proportions of HPV16-
positive, HPV18-positive, and other HPV-positive cases of CIS/
AIS and invasive cancer varied by calendar year of diagnosis, age at 
diagnosis, ethnicity, histology, and stage (  Table 6  ). Remarkably, 
  Table 2    .       Relative risks of CIS/AIS and invasive cervical cancer for individual HPV genotypes expressed as the percent risk relative to 
HPV16  *     
    HPV type
Control subjects 
(N = 4007)   
CIS/AIS case 
subjects (N = 1213)   
Invasive cancer case 
subjects (N = 808)    CIS/AIS 
RR (95% CI)
Invasive cancer 
RR (95% CI)      n (%) n (%) n (%)
    16 297 (7.4) 683 (56.3) 430 (53.2) 100 (referent) 100 (referent) 
  06 80 (2.0) 12 (1.0) 4 (0.5) 1 (0 to 2) 0 (0 to 2) 
  11    †    18 (0.4) 14 (1.2) 1 (0.1) 7 (2 to 21) 0 (0 to 4) 
  18 91 (2.3) 72 (5.9) 106 (13.1) 14 (9 to 21) 68 (47 to 100) 
  31 117 (2.9) 153 (12.6) 35 (4.3) 43 (31 to 60) 8 (5 to 14) 
  33 37 (0.9) 97 (8.0) 32 (4.0) 101 (62 to 163) 57 (30 to 107) 
  35 39 (1.0) 42 (3.5) 14 (1.7) 41 (24 to 72) 22 (11 to 47) 
  39 132 (3.3) 20 (1.6) 22 (2.7) 1 (0 to 2) 5 (2 to 9) 
  40    ‡    ,  §  23 (0.6) 1 (0.1) 0 (0.0) 0 (0 to 2)   —   
  42    †    ,    ‡    48 (1.2) 3 (0.2) 1 (0.1) 0 (0 to 1) 0 (0 to 2) 
  45 90 (2.2) 37 (3.1) 49 (6.1) 7 (4 to 13) 32 (20 to 53) 
  51 120 (3.0) 59 (4.9) 9 (1.1) 9 (6 to 15) 2 (1 to 4) 
  52 118 (2.9) 64 (5.3) 24 (3.0) 11 (7 to 16) 6 (3 to 11) 
  53 197 (4.9) 28 (2.3) 9 (1.1) 1 (1 to 2) 0 (0 to 1) 
  54 140 (3.5) 3 (0.2) 2 (0.2) 0 (0 to 0) 0 (0 to 1) 
  56 96 (2.4) 20 (1.6) 9 (1.1) 2 (1 to 5) 3 (1 to 8) 
  58 100 (2.5) 66 (5.4) 20 (2.5) 15 (9 to 22) 2 (1 to 5) 
  59 84 (2.1) 17 (1.4) 15 (1.9) 2 (1 to 5) 7 (3 to 14) 
  66 91 (2.3) 13 (1.1) 2 (0.2) 1 (0 to 2) 0 (0 to 1) 
  68/73 86 (2.1) 27 (2.2) 13 (1.6) 3 (2 to 6) 6 (3 to 12) 
  All other types 646 (16.1) 35 (2.9) 7 (0.9) 0 (0 to 0) 0 (0 to 0) 
  PCR negative    ||    2470 (61.6) 35 (2.9) 73 (9.0) 0 (0 to 0) 0 (0 to 1)   
    *     RRs are given as percentage. CIS/AIS = carcinoma in situ or adenocarcinoma in situ; HPV = human papillomavirus;   —   = not applicable; RR = relative risk; 
CI = confidence interval; PCR = polymerase chain reaction.   
      †       Not found as a single genotype infection in invasive cancers.   
      ‡       Not found as a single genotype infection in CIS/AIS.   
    §     Not found in invasive cancer and was not included in the logistic regression model.   
      ||       On pathology review, 14 of the 35 CIS/AIS and 8 of the 73 invasive cancers had no tumor present in the final hematoxylin-eosin  –  stained section.     482   Articles | JNCI  Vol. 101, Issue 7  |  April 1, 2009
the proportion of HPV16-positive cases declined with more recent 
calendar year of diagnosis, whereas the proportion of cases posi-
tive for HPV genotypes other than HPV16 or 18 increased. The 
proportion of HPV18-positive cases showed no clear trend by 
calendar year of diagnosis. The proportion of HPV16-positive 
precancers and cancers diagnosed during 1980  –  1984 was 68.5% 
compared with 53% during 1995  –  2000. The proportions of 
HPV16- and HPV18-positive cases declined with increasing age at 
diagnosis, which is consistent with the data presented in   Table 5  . 
There was a greater prevalence of HPV16-positive cases diagnosed 
in non-Hispanic white women than in Hispanic women (57.8% 
and 51.3%, respectively). The combined proportions of HPV16-
positive and HPV18-positive cases was greater in glandular (eg, 
adenocarcinoma) and adenosquamous histology than in squamous 
cell histology (71.9% and 63.3%, respectively), which reﬂ  ects the 
greater contribution of HPV18 to glandular disease than to 
squamous cell disease (26.7% and 6.2%, respectively). The pro-
portion of HPV18-positive CIS/AIS cases (5.3%) was lower than 
the proportions of HPV18-positive local-stage (10.5%), regional-
stage (14.5%), or distant-stage (13.5%) invasive cancers.         
  The proportions of HPV16-related alpha-9 and HPV18-
related alpha-7 genotype  –  positive cases remained relatively con-
stant by calendar period of diagnosis (  Table 6  ). This ﬁ  nding 
suggests that the shift in more recent years from HPV16 and 18 
to other HPV genotypes was attributable to other genotypes in 
the alpha-9 and alpha-7 phylogenetic species rather than to 
genotypes in the other phylogenetic species that contain carcino-
genic HPV genotypes (ie, alpha-5 and alpha-6). In addition, the 
fact that the proportion of disease at diagnosis due to the other 
HPV species increased from 3.6% in women aged 30  –  39 years to 
8.4% in women aged 50  –  59 years, to 26.7% in women aged 
80 years or older suggests that alpha-5 and alpha-6 HPV geno-
types not only rarely cause cancer but also are very weak carcino-
gens that take a prolonged time for precancerous lesions to 
develop into cancer.   
    Discussion 
  We conducted a study of HPV genotype patterns in invasive 
cervical cancer and its immediate precursor lesion, CIS. To our 
knowledge, this is the largest study of this kind conducted in a 
US population. The size of this study permitted us to examine 
HPV genotype patterns in both squamous cell and glandular cell 
histology. Our findings have direct implications for past and future 
patterns of cervical cancer incidence and prevention. 
  We conﬁ  rmed that HPV genotypes HPV16, 18, 31, 33, 35, 45, 
52, and 58 were associated with a high risk of cervical CIS/AIS. In 
addition, the greatest risk of developing invasive cervical cancer was 
among women who were positive for HPV genotypes 16, 18, 33, 35, 
and 45. For CIS/AIS, the mean age at diagnosis did not differ among 
cases that were positive for HPV16, 18, or other carcinogenic HPV 
genotypes. By contrast, we found that HPV16- and HPV18-positive 
invasive cancers were more prevalent in younger women than inva-
sive cancers related to other carcinogenic non-HPV16/18 geno-
types. One possible explanation for this age shift is that there may be 
a longer sojourn time at each stage of cervical carcinogenesis for 
these less carcinogenic HPV genotypes. It is also possible that these 
weaker carcinogens are more dependent on secondary factors, such 
as smoking (  25  ,  26  ). Alternatively, other carcinogenic HPV geno-
types may take longer to establish causal infections because of their 
lower prevalence in the general population. In support of our ﬁ  nd-
ings, two very recent reports demonstrated a younger mean or 
median age at diagnosis for HPV 16 and 18 cancers (  27  ,  28  ). One of 
these studies also showed that the integration frequency of various 
HPV genotypes was strongly associated with age at diagnosis of 
cancer and presumably with malignant potential (  27  ). 
  Table 3    .       Relative risks of CIS/AIS and invasive cervical cancer for HPV phylogenetic species expressed as the percent risk relative to 
HPV16  *     
    HPV species
Control subjects 
(N = 4007)   
CIS/AIS case 
subjects (N = 1213)   
Invasive cancer case 
subjects (N = 808)    CIS/AIS
RR (95% CI)
Invasive cancer   
RR (95% CI)      n (%) n (%) n (%)
  HPV16 297 (7.4) 683 (56.3) 430 (53.2) 100 (referent) 100 (referent) 
  Alpha-1 48 (1.2) 3 (0.2) 1 (0.1) 0 (0 to 1) 0 (0 to 2) 
  Alpha-3 510 (12.7) 12 (1.0) 4 (0.5) 0 (0 to 0) 0 (0 to 0) 
  Alpha-4    †    1 (0.0) 1 (0.1) 0 (0.0) 59 (2 to >999)   —   
  Alpha-5 160 (4.0) 74 (6.1) 10 (1.2) 6 (4 to 9) 1 (0 to 2) 
  Alpha-6 342 (8.5) 60 (4.9) 20 (2.5) 1 (1 to 1) 1 (0 to 1) 
  Alpha-7 466 (11.6) 152 (12.5) 191 (23.6) 3 (2 to 4) 19 (15 to 26) 
  Alpha-8    †    23 (0.6) 1 (0.1) 0 (0.0) 0 (0 to 1)   —   
  Alpha-9    ‡    312 (7.8) 342 (28.2) 100 (12.4) 49 (39 to 62) 19 (14 to 25) 
  Alpha-10 140 (3.5) 30 (2.5) 6 (0.7) 1 (1 to 2) 0 (0 to 1) 
  Alpha-11 44 (1.1) 17 (1.4) 7 (0.9) 3 (1 to 7) 5 (2 to 15) 
  Alpha-13 140 (3.5) 3 (0.2) 2 (0.2) 0 (0 to 0) 0 (0 to 1) 
  Alpha-15    †    ,  §  7 (0.2) 0 (0.0) 0 (0.0)   —   —   
  PCR negative 2470 (61.6) 35 (2.9) 73 (9.0) 0 (0 to 0) 0 (0 to 0)   
    *     RRs are given as percentage. CIS/AIS = carcinoma in situ or adenocarcinoma in situ; HPV = human papillomavirus;   —   = not applicable; RR = relative risk; 
CI = confidence interval; PCR = polymerase chain reaction.   
      †       Not found in invasive cancer and was not included in the logistic regression model.   
      ‡       Excludes HPV16.   
    §     Not found in CIS/AIS and was not included in the logistic regression model.     jnci.oxfordjournals.org    JNCI | Articles 483
  Regardless of the reason for the age shift, we suggest that it may 
be reasonable to consider increasing the age at initiation of cervical 
screening programs (ie, currently 21 years of age in the United 
States or within 3 years of beginning sexual activity) in HPV-
vaccinated populations for several reasons. First, in unvaccinated 
populations, the incidence of cervical cancer in women younger 
than 25 years is extremely rare, approximately two in 100 000 (  22  ). 
It is reasonable to expect that the rates of cervical cancer in vacci-
nated women younger than 25 years will be reduced by 50%, to 
one in 100 000, which is similar to the rate of vaginal cancer (  22  ). 
By analogy to vaginal cancer, for which screening is not recom-
mended, screening in young, vaccinated women should be discour-
aged. Second, screening is not currently preventing these rare cases 
of cancer in younger women (  22  ). Third, the prevention of these 
rare cases of cervical cancer must be weighed against iatrogenic 
morbidity due to overtreatment by excision of benign lesions. 
Unfortunately, aggressive cervical screening in this relatively low-
risk reproductive-age population leads to the overdetection of his-
tological changes, such as cervical intraepithelial neoplasia (CIN) 
grade 2 (CIN2), that often result from recent HPV infections. The 
diagnosis of CIN2 has been shown to be highly heterogeneous, not 
reproducible among pathologists (  29  ), and is associated with an 
intermediate risk of cancer compared with a diagnosis of CIN3 
(  30  ). CIN2 diagnoses include occult cervical precancers and, there-
fore, a CIN2 diagnosis represents a mandatory threshold that trig-
gers ablative or excisional treatment under current clinical 
management guidelines (  31  ). However, excisional treatment of 
high-grade lesions has been shown to negatively impact reproduc-
tive outcomes by increasing risks of premature rupture of mem-
branes, low  –  birth weight infants, and preterm delivery (  32  ). 
  It is also worth noting that the positive predictive values or the 
posttest probabilities of disease for cytology and HPV testing are 
expected to decrease in vaccinated populations (  33  ,  34  ) because the 
primary beneﬁ   ts of screening are related to the detection of 
HPV16. Because of this decrease and because the cancers caused 
by carcinogenic HPV genotypes other than HPV16 and 18 repre-
sent about one-third of cases currently diagnosed in women 
younger than 30 years of age, the cost-effectiveness of screening 
younger women is likely to decrease dramatically (  35  ). Increasing 
the age at initial screening in vaccinated populations will undoubt-
edly allow some cases of precancer and cancer to go undiagnosed 
in younger women. However, as many as 60% of cases (  36  ,  37  ) of 
invasive cervical cancer diagnosed today are detected, regardless of 
age, in women who have never received a Papanicolaou test or who 
  Table 4    .       Relative risks of CIS/AIS and invasive cervical cancer for HPV risk groups expressed as the percentage risk relative to HPV16  *     
          Histological type and 
HPV risk group
Control subjects 
(N = 4007)   
CIS/AIS case 
subjects (N = 1213)   
Invasive cancer case 
subjects (N = 808)    CIS/AIS 
RR (95% CI)
Invasive cancer   
RR (95% CI)      n (%) n (%) n (%)
    All histologic types        
         PCR negative 2470 (61.6) 35 (2.9) 73 (9.0) 0 (0 to 0) 0 (0 to 0) 
         Noncarcinogenic 536 (13.4) 30 (2.5) 16 (2.0) 2 (2 to 3) 2 (1 to 3) 
         Carcinogenic    †    635 (15.8) 409 (33.7) 184 (22.8) 30 (25 to 36) 21 (17 to 26) 
         HPV18 69 (1.7) 56 (4.6) 105 (13.0) 35 (24 to 52) 100 (71 to 140) 
         HPV16 297 (7.4) 683 (56.3) 430 (53.2) 100 (referent) 100 (referent) 
  Control subjects 
(N = 4007)   
CIS case subjects 
(N = 1163)   
Invasive cancer case 
subjects (N = 660)    CIS 
RR (95% CI)
Invasive cancer   
RR (95% CI)    n (%) n (%) n (%)
  Squamous cell        
         PCR negative 2470 (6.6) 34 (2.9) 32 (4.8) 0 (0 to 0) 0 (0 to 0) 
         Noncarcinogenic 536 (13.4) 27 (2.3) 16 (2.4) 2 (1 to 3) 2 (1 to 4) 
         Carcinogenic    †    635 (15.8) 400 (34.4) 164 (24.8) 30 (25 to 36) 21 (16 to 26) 
         HPV18 69 (1.7) 44 (3.8) 65 (9.8) 28 (19 to 43) 70 (48 to 102) 
         HPV16 297 (7.4) 658 (56.6) 383 (58.0) 100 (referent) 100 (referent) 
  Control subjects 
(N = 4007)   
AIS case subjects 
(N = 25)   
Invasive cancer case 
subjects (N = 122)    AIS 
RR (95% CI)
Invasive cancer   
RR (95% CI)    n (%) n (%) n (%)
  Adenocarcinoma or 
  adenosquamous    ‡   
       
         PCR negative 2470 (61.6) 0 (0.0) 32 (26.2) 0 (0 to 3) 9 (5 to 14) 
         Noncarcinogenic 536 (13.4) 1 (4.0) 0 (0.0) 5 (0 to 32) 0 (0 to 4) 
         Carcinogenic    †    635 (15.8) 0 (0.0) 11 (9.0) 0 (0 to 13) 11 (5 to 23) 
         HPV18 69 (1.7) 12 (48.0) 34 (27.9) 430 (168 to 1092) 325 (187 to 561) 
         HPV16 297 (7.4) 12 (48.0) 45 (36.9) 100 (referent) 100 (referent)   
    *     The human papillomavirus (HPV) risk group is defined as a hierarchical classification: HPV16 > HPV18 > carcinogenic HPV except HPV16 and HPV18 > noncarcino-
genic HPV > HPV negative. Note that this is a hierarchical classification and that the number in the HPV18 category excludes those with HPV16 coinfection. RRs 
are given as percentage. CIS/AIS = carcinoma in situ or adenocarcinoma in situ; RR = relative risk; CI = confidence interval; PCR = polymerase chain reaction.   
      †       Excludes HPV16 and 18.   
      ‡       Due to the small number of cases, relative risks for adenocarcinoma and adenosquamous were not adjusted for race.     484   Articles | JNCI  Vol. 101, Issue 7  |  April 1, 2009
have failed to obtain a Papanicolaou test within intervals recom-
mended by current US screening guidelines. Thus, a majority of 
cancer cases caused by carcinogenic HPV types other than HPV16 
or 18 will potentially be diagnosed if vaccinated women fail to 
attend regular screening. 
  In this study, we found evidence that the fraction of HPV16-
positive cancers in New Mexico decreased from the early 1980s to 
the late 1990s. One possible explanation for this secular trend is 
that implementation of cytology-based screening and treatment 
led to this pattern. Cytology screening programs were initiated in 
the 1950s in the United States and achieved high coverage during 
the time period of this study (ie, 1980  –  2000). Rates of invasive 
cervical cancer in New Mexico peaked in the late 1970s, presum-
ably when cytology screening was achieving broad population 
coverage, and has declined steadily from the 1980s onward (  22  ). It 
is plausible that the most carcinogenic HPV genotype, HPV16, 
would be more likely to be detected and therefore censored for 
cancer outcomes by programs with good screening coverage. This 
may be especially true of HPV16 infection, which is more likely to 
result in abnormalities that trigger clinical action, such as HSIL 
cytology (  21  ) and noticeable lesions on colposcopic examination 
(  38  ). Ongoing surveillance to assess potential HPV16 and 18 dis-
ease replacement with nonvaccine HPV genotypes following wide-
spread implementation of HPV16/18 vaccination must compare 
population-based HPV genotype  –  speciﬁ   c prevalence in women 
diagnosed with CIN1 or worse vs women with asymptomatic HPV 
infections (ie, normal cytology). Our results suggest that this sur-
veillance must also adjust for the impact of changing screening 
practices on HPV genotype  –  speciﬁ  c time trends. 
  We conﬁ  rmed and extended previous observations (  4  ,  39  ) that 
HPV18 is underrepresented in precancerous lesions compared with 
its presence in invasive cancers. Upon further examination, we found 
a more complex relationship between HPV phylogenetic species and 
different histologic types. Speciﬁ  cally, we found a general character-
istic phenotype for alpha-7 HPV genotypes, which is composed of 
HPV18, 39, 45, 59, 68, and 70, because exclusion of HPV18 did not 
meaningfully change the prevalence ratio of invasive cancer to CIS/
AIS. We also found that this high prevalence ratio was only observed 
in squamous cell histology, not in glandular cell histology. 
  The deﬁ  cit of alpha-7 genotype  –  positive CIS has several pos-
sible explanations. Alpha-7 genotype  –  positive CIS appear to be 
harder to detect by cervical screening than CIS related to other 
HPV genotypes. Alternatively, as others have suggested, alpha-7 
genotypes, especially HPV18, progress more rapidly from infec-
tion to invasive cervical cancer (  4  ,  40  ). There is also evidence sug-
gesting that alpha-7 HPV genotypes are less likely to cause 
cytologic HSIL than other HPV genotypes. In particular, Khan 
et al. (  41  ) noted a lag time in the development HPV18-related 
  Table 5    .       Mean age at diagnosis of CIS/AIS and invasive cervical cancer from analysis of variance models  *     
    Characteristic N
CIS/AIS   
N
Invasive cancer     
  Mean (95% CI) Mean (95% CI) 
  All study subjects 1213 32.2 (31.5 to 32.8) 808 49.6 (48.4 to 50.7) 
  HPV risk group       
         HPV negative 35 32.4 (28.8 to 35.9) 73 55.4 (51.7 to 59.2) 
         Noncarcinogenic 30 36.0 (32.1 to 39.8) 16 53.3 (45.6 to 61.0) 
         Carcinogenic (excluding 16 and 18) 409 32.8 (31.7 to 33.8) 184 52.3 (50.0 to 54.6) 
         HPV18 positive 56 32.0 (29.0 to 35.0) 105 45.9 (42.9 to 49.0) 
         HPV16 positive 683 31.6 (30.8 to 32.4) 430 48.1 (46.6 to 49.6) 
     P   = .15     P   < .001 
  Ethnicity       
         Hispanic 499 30.5 (29.6 to 31.5) 337 49.3 (47.6 to 50.9) 
         Non-Hispanic white 714 33.3 (32.5 to 34.1) 471 49.8 (48.4 to 51.2) 
     P   < .001     P   = .65 
  Histology       
         Squamous cell 1163 32.1 (31.4 to 32.7) 660 49.6 (48.4 to 50.8) 
         Adenocarcinoma 23 33.2 (28.5 to 37.9) 101 51.5 (48.3 to 54.8) 
         Adenosquamous 2 34.1 (19.1 to 49.1) 21 45.5 (38.8 to 52.2) 
         Other 25 35.2 (31.0 to 39.5) 26 44.4 (38.2 to 50.6) 
     P   = .50     P   = .13 
  Stage at diagnosis for invasive cancer       
         Local    —  477 45.2 (43.8 to 46.6) 
         Regional    —  269 55.9 (54.0 to 57.8) 
         Distant    —  47 55.1 (50.6 to 59.6) 
  Unknown    —  15 56.3 (48.3 to 64.4) 
         P   < .001 
  Year of diagnosis       
         1980  –  1984 0   —  100 52.3 (49.3 to 55.4) 
         1985  –  1989 173 33.0 (31.4 to 34.7) 183 48.2 (45.9 to 50.5) 
         1990  –  1994 391 31.7 (30.6 to 32.8) 299 49.6 (47.8 to 51.4) 
         1995  –  2000 649 32.2 (31.3 to 33.0) 226 49.4 (47.3 to 51.4) 
     P   = .41     P   = .21   
    *     Least squares mean age is given in years and is adjusted to the observed marginal distribution of the covariates.   P   values are for the F test using the type III 
sums of squares. CIS/AIS = carcinoma in situ or adenocarcinoma in situ; HPV = human papillomavirus; CI = confidence interval;   —   = not applicable.     jnci.oxfordjournals.org    JNCI | Articles 485
CIN3 or worse compared with HPV16-related CIN3 or worse      , 
which argues in favor of poorer detection and against more rapid 
progression. We found that invasive cancers related to alpha-7 
genotypes were more likely to be diagnosed with regional or dis-
tant metastasis than alpha-9  –  related cancers, further evidence of 
poorer detection of alpha-7  –  related disease. If poorer detection of 
alpha-7 precancerous lesions by cytology is the cause of the dearth 
of alpha-7  –  related CIS, we would anticipate that the use of HPV 
testing in primary cervical cancer screening could result in an 
increase in detection, assuming equal analytic sensitivity for 
alpha-7 and non  –  alpha-7 carcinogenic HPV genotypes. 
  Despite the overall decline in cervical cancer rates in Western 
countries, the decrease has been restricted to the more common 
squamous cell carcinoma and there is evidence of increasing rates of 
adenocarcinoma in the United States (  42  ) and Europe (  43  ). The 
etiology of these increases remains unexplained, although several 
hypotheses are plausible based on epidemiological risk factors (  44    –
    46  ). In this study, as previously reported (  2    –    7  ), we found that alpha-7 
HPV genotypes were more strongly associated with adenocarci-
noma than alpha-9 HPV genotypes. These data, along with evidence 
that other factors (  44    –    46  ), including contraceptive hormones, may 
elevate the risk for adenocarcinoma relative to that for squamous cell 
carcinoma and the secular increases in exposure to these risk factors 
may explain the increase in adenocarcinoma in Western countries. 
Studies of the molecular and statistical interactions between the use 
of oral contraceptive hormones and alpha-7 HPV genotypes may 
help elucidate the underlying biological mechanisms. 
  Our study has some limitations. First, our study was restricted 
to Hispanic and non-Hispanic white women residing in New 
Mexico, and thus our ﬁ  ndings may not be generalizable to other 
populations. Second, because of the cross-sectional nature of 
this study, we can only infer relationships between time and 
  Table 6    .       Predicted marginal proportions of HPV type from multinomial logistic regression models  *     
    Variable N
Model 1    †        Model 2    ‡         









  % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)   
    Year of diagnosis             
         1980  –  1984 100 68.5 (59.5 to 77.5) 8.1 (3.4 to 12.8) 20.3 (12.1 to 28.5) 82.8 (76.1 to 89.5) 8.1 (3.8 to 12.4) 6.1 (1.2 to 11.0) 
         1985  –  1989 356 60.9 (55.8 to 66.0) 6.8 (4.3 to 9.3) 26.6 (21.9 to 31.3) 78.3 (74.2 to 82.4) 12.0 (8.7 to 15.3) 3.9 (1.9 to 5.9) 
         1990  –  1994 690 53.1 (49.4 to 56.8) 9.5 (7.3 to 11.7) 31.2 (27.7 to 34.7) 74.8 (71.7 to 77.9) 14.2 (11.7 to 16.7) 4.7 (3.1 to 6.3) 
         1995  –  2000 875 53.0 (49.7 to 56.3) 7.1 (5.3 to 8.9) 35.0 (31.9 to 38.1) 77.1 (74.2 to 80.0) 12.5 (10.1 to 14.9) 5.5 (3.9 to 7.1) 
      P   = .009   P   = .25 
  Age at diagnosis, y             
         <20 67 60.4 (48.6 to 72.2) 5.5 (0.0 to 12.8) 29.3 (19.3 to 39.3) 74.5 (63.1 to 85.9) 13.9 (3.1 to 24.7) 7.0 (1.5 to 12.5) 
         20  –  29 593 56.7 (52.4 to 61.0) 8.8 (6.1 to 11.5) 29.6 (25.9 to 33.3) 78.7 (75.0 to 82.4) 12.5 (9.2 to 15.8) 3.8 (2.2 to 5.4) 
         30  –  39 604 58.6 (54.7 to 62.5) 9.1 (6.7 to 11.5) 29.7 (26.2 to 33.2) 79.6 (76.5 to 82.7) 14.3 (11.4 to 17.2) 3.6 (2.2 to 5.0) 
         40  –  49 306 53.9 (48.2 to 59.6) 11.7 (8.4 to 15.0) 27.9 (22.8 to 33.0) 72.2 (67.3 to 77.1) 17.0 (13.1 to 20.9) 4.3 (1.9 to 6.7) 
         50  –  59 178 50.4 (42.8 to 58.0) 6.9 (4.0 to 9.8) 37.0 (29.6 to 44.4) 71.5 (64.8 to 78.2) 14.2 (9.7 to 18.7) 8.4 (3.5 to 13.3) 
         60  –  69 146 45.1 (36.7 to 53.5) 3.6 (1.2 to 6.0) 43.5 (34.9 to 52.1) 75.0 (67.6 to 82.4) 8.4 (4.7 to 12.1) 8.6 (2.7 to 14.5) 
         70  –  79 86 44.5 (32.9 to 56.1) 4.9 (1.2 to 8.6) 43.8 (32.2 to 55.4) 74.9 (64.7 to 85.1) 6.6 (2.7 to 10.5) 12.0 (3.0 to 21.0) 
           ≥  80 41 40.4 (24.5 to 56.3) 1.3 (0.0 to 3.8) 46.0 (30.1 to 61.9) 60.8 (43.7 to 77.9) 1.2 (0.0 to 3.6) 26.7 (9.8 to 43.6) 
      P   < .001   P   < .001 
  Ethnicity             
         Non-Hispanic white 1185 57.8 (55.1 to 60.5) 8.2 (6.6 to 9.8) 28.9 (26.4 to 31.4) 77.1 (74.7 to 79.5) 12.6 (10.8 to 14.4) 5.3 (3.9 to 6.7) 
         Hispanic 836 51.3 (48.0 to 54.6) 7.6 (5.8 to 9.4) 35.3 (32.2 to 38.4) 76.7 (74.0 to 79.4) 12.9 (10.5 to 15.3) 4.6 (3.2 to 6.0) 
      P   = .01   P   = .77 
  Histology             
         Squamous cell 1823 57.1 (54.7 to 59.5) 6.2 (5.0 to 7.4) 33.0 (30.8 to 35.2) 79.8 (77.8 to 81.8) 11.3 (9.7 to 12.9) 5.2 (4.2 to 6.2) 
         Adenocarcinoma or 
  adenosquamous
147 45.2 (36.6 to 53.8) 26.7 (18.9 to 34.5)10.3 (4.8 to 15.8) 53.9 (45.5 to 62.3) 26.4 (19.0 to 33.8) 1.6 (0.0 to 4.0) 
         Other 51 29.5 (17.0 to 42.0) 10.8 (3.0 to 18.6) 42.3 (28.8 to 55.8) 56.7 (44.2 to 69.2) 16.6 (7.4 to 25.8) 9.5 (0.5 to 18.5) 
      P   < .001   P   < .001 
  Stage at diagnosis             
         In situ 1213 55.0 (51.9 to 58.1) 5.3 (3.9 to 6.7) 35.7 (32.8 to 38.6) 82.2 (79.7 to 84.7) 7.2 (5.6 to 8.8) 6.7 (4.7 to 8.7) 
         Localized 477 58.6 (53.9 to 63.3) 10.5 (7.6 to 13.4) 25.0 (20.7 to 29.3) 71.8 (67.5 to 76.1) 18.5 (14.8 to 22.2) 3.9 (1.9 to 5.9) 
         Regional 269 54.0 (47.3 to 60.7) 14.5 (9.6 to 19.4) 24.7 (19.2 to 30.2) 63.7 (57.0 to 70.4) 26.6 (20.1 to 33.1) 2.9 (1.1 to 4.7) 
         Distant 47 44.0 (28.9 to 59.1) 13.5 (3.1 to 23.9) 30.1 (16.4 to 43.8) 60.4 (45.5 to 75.3) 27.5 (13.6 to 41.4) 0.0 (0.0 to 0.0) 
         Invasive, NOS 15 55.8 (30.9 to 80.7) 6.4 (0.0 to 17.0) 32.3 (8.6 to 56.0) 81.6 (63.0 to 100.0) 13.3 (0.0 to 30.9) 0.0 (0.0 to 0.0) 
      P   < .001   P   < .001   
    *     HPV = human papillomavirus; CI = confidence interval; NOS = not otherwise specified.   P   values are for the Wald F test of the association between the variable 
(eg, age) and the distribution of HPV genotype or group of phenotypes.   
      †       Categories are defined in a hierarchical manner: HPV16 > HPV18 > other HPV > HPV negative. Marginal proportions are not shown for the HPV negative category 
but can be obtained by summing the other three proportions and subtracting from 100.   
      ‡       Categories are defined in a hierarchical manner: Alpha-9 > alpha-7 > other HPV > HPV negative. Marginal proportions are not shown for the HPV negative cat-
egory but can be obtained by summing the other three proportions and subtracting from 100.     486   Articles | JNCI  Vol. 101, Issue 7  |  April 1, 2009
outcomes. For example, our data suggest that cases positive for 
HPV genotypes other than HPV16 and 18 arise on average at an 
older age than those positive for HPV16 and 18. There is clearly 
a wide variation in the sojourn time between the causal infection 
and the diagnosis of cancer across the carcinogenic HPV geno-
types, which may preclude using the knowledge of HPV geno-
types to reliably predict the age-speciﬁ  c risks of invasive cancer. 
It is noteworthy that our ﬁ  nding of a difference in the mean ages 
at diagnosis between cancers positive for HPV16 or 18 and those 
positive for other HPV genotypes applies only to (relatively) well-
screened populations such as this population study conducted in 
New Mexico. Low rates of progression from CIS/AIS to cancer 
and the age at diagnosis are undoubtedly strongly inﬂ  uenced by 
the censoring of CIS/AIS diagnoses, which is probably con-
founded by the carcinogenicity of each HPV genotype and the 
ability to detect HPV-related CIS/AIS in a timely fashion. To 
examine the impact of screening on HPV genotype distributions 
in cervical cancer, ongoing large international case series should 
analyze the distribution of HPV genotypes in relation to the his-
tory and quality of screening. Third, interpretation of the case  – 
control odds ratio as a relative risk requires that the relative 
prevalence of HPV genotypes in the control sample be equal to 
the relative exposure to HPV genotypes in the source population 
of the cases. Our control subjects were selected over a time period 
(1996  –  2000) that was more recent than the time period during 
which most of the case subjects were presumably exposed to 
HPV. Thus, the interpretation of our odds ratios as relative risks 
requires that the relative prevalence of the circulating HPV geno-
types remain stable over an extended time period. However, 
because we used HPV16-positive subjects as the referent group, 
it is not necessary to assume that the absolute prevalence of HPV 
has remained static. Recent data from A Randomized Trial In 
Screening to Improve Cytology (ARTISTIC) (  47  ) lend support 
to the assumption of stability in the relative prevalence of HPV 
genotypes across time even if the overall prevalence of HPV 
infections has increased during the past 20  –  40 years as has been 
suggested by some (  48  ). In the ARTISTIC trial, there were rela-
tively minor differences in HPV genotype distribution between 
HPV-positive women 40 years or older and those younger than 
40 years. Fourth, the prevalence of HPV genotypes in the control 
sample is a point-in-time prevalence and may differ from the 
cumulative exposure of the case subjects to these HPV genotypes. 
For the less frequently observed HPV genotypes, the control 
sample may underestimate the cumulative exposure in the source 
population of the cases and result in an overestimate of the rela-
tive risk. Finally, we also note that multiple HPV genotypes were 
detected in 16% of the samples. These multiple coinfections 
undoubtedly led to misattribution of some cases of CIS/AIS and 
cancer to HPV16 and 18, which would be expected to inﬂ  ate the 
relative risks and diminish the differences in ages at diagnosis for 
HPV16- and HPV18-related cancers. A recent systematic review 
of the published HPV genotype prevalence data among cervical, 
vaginal, and vulvar precancers and cancers in the United States 
highlighted issues related to HPV coinfections when assigning 
disease attribution (  49  ). 
  This study of HPV genotypes in New Mexico provides important 
baseline data for evaluating the effectiveness of newly implemented 
HPV-based technologies, HPV vaccines, and HPV screening in 
the prevention of cervical cancer. Moreover, these data can guide 
the future application of these technologies to maximize the cost-
effective, public health beneﬁ  ts of these interventions.         
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